PATENT CLAIM ANALYSIS

Application Number: 15903662
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-06
Patent Classification: ["514", "317000"]

Abstract:
This invention relates to improvements in therapeutic neurological and neuropsychic treatments using acetylcholinesterase inhibitors. More specifically, the invention enables the effects of the reversible acetylcholinesterase inhibitor donepezil to be potentiated by certain molecules, referred to here as connexin-blocking agents. Said connexin-blocking agent is preferably meclofenamic acid.

Claim (Index 25):
The method according to  claim 22 , wherein the donepezil or a pharmaceutical salt thereof and mefloquine are coadministered simultaneously as separate dosages.

Metadata:
- Claim Count in Document: 26.0
- Percentile: 88.0
- Lexical Diversity: 1.2439
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14479614', '14861169', '12758631', '14218083', '16320949']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7575985211738216
- 35 USC 102 Novelty (BERT): 0.5075419727277183
- Combined Prediction Score: 0.7325928663292114
- Mean Citation Score: 200.030694
- Max Citation Score: 205.81007
- Similarity Product: 120.9048486872983

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test